Ecog-Acrin Medical Research Foundation, Inc.

Ecog-Acrin Medical Research Foundation, Inc. is a Philadelphia-based non-profit medical research foundation that operates as a federal grant recipient and occasional prime contractor on National Institutes of Health and Defense Health Agency cancer research programs, with a secondary presence as a subrecipient on multi-institutional clinical trials and translational science initiatives. The organization holds no federal contract vehicles and operates predominantly in a subrecipient role (58% of recent awards), with the bulk of federal engagement routed through the National Cancer Institute as part of the National Clinical Trials Network (NCTN) infrastructure.

Ecog-Acrin's federal footprint concentrates almost entirely on the National Cancer Institute (17 of 19 awards), with a single cooperative agreement from the Food and Drug Administration's Center for Drug Evaluation and Research and a project grant from the Defense Health Agency. The organization's work centers on precision oncology, clinical trial operations and data management, real-world evidence generation for cancer therapeutics, and health equity in cancer research enrollment. As a prime grant recipient, Ecog-Acrin holds a $3,644,169 project grant (CFDA 12.420, Military Medical Research and Development) supporting a four-year extension to the TAILORx breast cancer study under the Defense Health Agency, awarded September 2023 with completion through September 2027. The organization also received a cooperative agreement from FDA's Center for Drug Evaluation and Research for real-world data and real-world evidence generation in cancer regulatory decision-making (awarded September 2023, completing August 2026), and a cooperative agreement from the National Cancer Institute supporting the ECOG-ACRIN Support Trial, a multilevel intervention to improve diverse enrollment in NCI-supported cancer clinical trials across head and neck, thoracic, and genitourinary cancers, and leukemia and myeloma (awarded September 2022, completing August 2028). In June 2026, Ecog-Acrin received a $21,660.69 National Cancer Institute purchase order for digital transfer and pathological image analysis from 1,154 clear cell kidney cancer patients, with delivery due December 2026.

Ecog-Acrin functions as a subrecipient on multiple Dana-Farber Cancer Institute and University of Washington clinical research programs managed through the National Cancer Institute. Subrecipient roles span clinical data management, case report form development, study build operations, protocol development, statistics and informatics support, and regulatory affairs for active NCI-supported therapeutic trials including ComboMATCH and MyeloMATCH patient registration studies. Across these sub-awards, Ecog-Acrin provides data management infrastructure—case report form development, database setup, edit check specification, standard operating procedure development, study chair coordination, and performance monitoring—to participating NCI institutions. The organization also provides translational science support, including support for a University of Michigan-led NCI-funded investigation into the genomic and social-environmental correlates of cancer outcomes in adolescent and young adult survivors.

Recent award activity shows growth through 2025 (six awards placed in 2025 across prime and sub roles) with four awards reaching ultimate completion inside the next twenty-four months. The organization's federal service contract footprint, as reported through the Service Contract Inventory, shows minimal SCI-reportable activity—one record in FY2022 involving approximately 0.1 FTEs on a named subcontract above the $150,000 reporting threshold. The organization's federal profile is narrowly concentrated on cancer research operations and clinical trial administration within the NCI portfolio rather than broader federal consulting or contracted services.